2026 Interim Report
Filed with HKEX · Stock code 2137 · · 73 pages · English
Corporate Profile Corporate Information Management Discussion and Analysis Corporate Governance and Other Information Page 2 3 5 20 Report on Review of Condensed Consolidated 45 Financial Statements Condensed Consolidated Statement of 46 Profit or Loss and Other Comprehensive Income Condensed Consolidated Statement of Financial Position Condensed Consolidated Statement of Changes in Equity Condens
Brii Biosciences Limited on 6ix
Earlier from Brii Biosciences
- Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
- Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
- Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
- Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Later from Brii Biosciences
- Notification Letter and Change Request Form for Registered Shareholders
- Notification Letter and Request Form for Non-registered Shareholders
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Grant of share options and restricted share units
- Next Day Disclosure Return
Follow Brii Biosciences into a list and get an email when it puts out news.
Follow Brii Biosciences